Drugs / 111In Zevalin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00477815 | May 2005 → Jul 2011 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 111In Zevalin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00477815 ↗ |
| Route | Intravenous | “Patients receive rituximab IV followed by a dosimetry dose of indium In 111 ibritumomab tiuxetan IV over 10 minutes on day -22.” NCT00477815 ↗ |